Crossmark

New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes

Crossref DOI link: https://doi.org/10.1007/s40273-018-0632-7

Published Online: 2018-03-08

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Varnava, Alice https://orcid.org/0000-0002-5090-9541
Bracchi, Robert

Samuels, Karen

Hughes, Dyfrig A. https://orcid.org/0000-0001-8247-7459
Routledge, Philip A. https://orcid.org/0000-0001-9770-6787
License Information

Text and Data Mining valid from 2018-03-08
More Information

Article History

First Online: 8 March 2018

Compliance with Ethical Standards

:

: This work received no specific grant from any funding agency in the public, commercial or not for-profit sectors.

: The All Wales Therapeutics and Toxicology Centre (AWTTC) acts as the secretariat to the All Wales Medicines Strategy Group (AWMSG). AV is employed by AWTTC as a medical writer. RB is employed by AWTTC as a medical advisor. KS is employed by AWTTC as Head of Patient Access to Medicines Service (PAMS). PAR led the team which established AWMSG in 2002 and is now employed by AWTTC as Clinical Director. DAH provides health economics support to AWTTC and receives an honorarium as a member of AWMSG. DAH is a Health and Care Research Wales Senior Research Leader.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.